Stockscreener 앱 받기
41.36
2.18%
-0.92
시간 외 거래:
41.74
0.38
+0.92%
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential - Yahoo Finance
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility - Yahoo Finance
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? - Yahoo Finance
2 Stocks That Could Soar This Year - The Globe and Mail
Dip Buying: Will Exelixis Inc stock recover after earningsMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Can Exelixis Inc. ride the EV waveEarnings Growth Summary & Risk Adjusted Swing Trade Ideas - mfd.ru
Exelixis Stock Likely To Go Higher On A Possible Key FDA Approval (NASDAQ:EXEL) - Seeking Alpha
What is the earnings history of Exelixis Inc.2025 Dividend Review & AI Forecasted Entry and Exit Points - mfd.ru
Aug Closing: Can Exelixis Inc sustain its profitabilityEarnings Risk Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 - BioSpace
Exelixis stock price target raised to $52 from $49 at H.C. Wainwright - Investing.com Canada
Exelixis and Summit Therapeutics: Future Prospects - Intellectia AI
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Analyst Expectations For Exelixis's Future - Benzinga
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
HC Wainwright & Co. Raises Price Target for Exelixis (EXEL) to $52 | EXEL Stock News - GuruFocus
Exelixis, Inc. (EXEL) Stock Analysis: A Healthcare Giant With A 3.03% Upside Potential - DirectorsTalk Interviews
Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity - Chartmill
Exelixis Charts Clinical Course for 2026 with Key Partnerships and Buyback - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Exelixis (EXEL) - The Globe and Mail
Guidance Update: Can Exelixis Inc sustain its profitabilityJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - baoquankhu1.vn
RBC Capital Maintains Exelixis(EXEL.US) With Hold Rating, Maintains Target Price $45 - 富途资讯
Exelixis: High-Growth Oncology Name Trading At A Discount (NASDAQ:EXEL) - Seeking Alpha
Precision Trading with Exelixis Inc. (EXEL) Risk Zones - Stock Traders Daily
How The New Price Target Is Shaping The Exelixis (EXEL) Investment Story - Yahoo Finance
Does Exelixis’ (EXEL) 2026 Zanzalintinib Rollout and Buybacks Shift Its Oncology Growth Narrative? - Sahm
Exelixis earns IBD stock rating upgrade - MSN
Investing in Exelixis (NASDAQ:EXEL) Three Years Ago Would Have Delivered You a 152% Gain - 富途资讯
Exelixis Earns IBD Stock Rating Upgrade - Investor's Business Daily
Exelixis Targets High-Risk Colorectal Cancer As Valuation Looks Undemanding - Sahm
Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch - Insider Monkey
Exelixis, Inc. (EXEL) Investor Outlook: Robust Revenue Growth and Strategic Partnerships Fuel Future Potential - DirectorsTalk Interviews
Top 10 Oncology Stocks to Buy Now - Insider Monkey
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup - Chartmill
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis, Inc. $EXEL Shares Sold by Nisa Investment Advisors LLC - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by EULAV Asset Management - MarketBeat
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise.com
Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL) - The Globe and Mail
Exelixis, Inc. (EXEL): A Bull Case Theory - Finviz
Growth Recap: Is Exelixis Inc a play on infrastructure spendingM&A Rumor & Weekly High Momentum Picks - baoquankhu1.vn
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity - Chartmill
Meritage Portfolio Management Has $12.20 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
InSilico Lands Drug Discovery Deal After Hong Kong IPO - Benzinga
Does Exelixis’ 2026 Revenue Guidance and Zanzalintinib Push Change The Bull Case For EXEL? - Sahm
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - MSN
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Finviz
Truist Securities raises Exelixis stock price target to $51 on oncology growth - Investing.com Canada
Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating - marketscreener.com
Exelixis, Inc. $EXEL Shares Sold by New York State Teachers Retirement System - MarketBeat
Citizens reiterates Market Outperform rating on Exelixis stock By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Lobbying Update: $30,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook - sharewise.com
EXEL: Franchise-focused oncology growth, strong 2025 results, and robust 2026 outlook driven by innovation - TradingView — Track All Markets
EXEL: Disciplined franchise strategy and strong pipeline drive growth in oncology markets - TradingView — Track All Markets
Exelixis cut to underperform at BofA on valuation and lack of catalysts - MSN
Exelixis (NASDAQ:EXEL) Shares Gap DownShould You Sell? - MarketBeat
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results and 2026 Guidance - TradingView
1.27%
자본화:
|
볼륨(24시간):